These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26109320)

  • 21. Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report.
    Letkiewicz S; Miedzybrodzki R; Fortuna W; Weber-Dabrowska B; Górski A
    Folia Microbiol (Praha); 2009 Sep; 54(5):457-61. PubMed ID: 19937220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.
    Burrowes B; Harper DR; Anderson J; McConville M; Enright MC
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):775-85. PubMed ID: 21905786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage endolysins: applications for food safety.
    Schmelcher M; Loessner MJ
    Curr Opin Biotechnol; 2016 Feb; 37():76-87. PubMed ID: 26707470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysis of cells of diverse bacteria by l,d-peptidases of Escherichia coli bacteriophages RB43, RB49 and T5.
    Shadrin VS; Machulin AV; Dorofeeva LV; Chernyshov SV; Mikoulinskaia GV
    J Appl Microbiol; 2021 Jun; 130(6):1902-1912. PubMed ID: 33107183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete genome sequence of a newly isolated lytic bacteriophage, EFAP-1 of Enterococcus faecalis, and antibacterial activity of its endolysin EFAL-1.
    Son JS; Jun SY; Kim EB; Park JE; Paik HR; Yoon SJ; Kang SH; Choi YJ
    J Appl Microbiol; 2010 May; 108(5):1769-79. PubMed ID: 19863688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of phage resistance in lactic acid bacteria.
    Moineau S
    Antonie Van Leeuwenhoek; 1999; 76(1-4):377-82. PubMed ID: 10532393
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of the first endolysin Cell Binding Domain (CBD) targeting Paenibacillus larvae.
    Santos SB; Oliveira A; Melo LDR; Azeredo J
    Sci Rep; 2019 Feb; 9(1):2568. PubMed ID: 30796258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria.
    Lai MJ; Lin NT; Hu A; Soo PC; Chen LK; Chen LH; Chang KC
    Appl Microbiol Biotechnol; 2011 Apr; 90(2):529-39. PubMed ID: 21264466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacteriophage lytic enzymes: novel anti-infectives.
    Fischetti VA
    Trends Microbiol; 2005 Oct; 13(10):491-6. PubMed ID: 16125935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cloning and Characterization of a Thermostable Endolysin of Bacteriophage TP-84 as a Potential Disinfectant and Biofilm-Removing Biological Agent.
    Żebrowska J; Żołnierkiewicz O; Ponikowska M; Puchalski M; Krawczun N; Makowska J; Skowron P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysins: the arrival of pathogen-directed anti-infectives.
    Pastagia M; Schuch R; Fischetti VA; Huang DB
    J Med Microbiol; 2013 Oct; 62(Pt 10):1506-1516. PubMed ID: 23813275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteriophage lysins as effective antibacterials.
    Fischetti VA
    Curr Opin Microbiol; 2008 Oct; 11(5):393-400. PubMed ID: 18824123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corrigendum: Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat Gram-positive spore forming bacteria.
    Nakonieczna A; Cooper CJ; Gryko R
    J Appl Microbiol; 2018 Jun; 124(6):1648. PubMed ID: 29745054
    [No Abstract]   [Full Text] [Related]  

  • 35. Spore-forming Bacilli and Clostridia in human disease.
    Mallozzi M; Viswanathan VK; Vedantam G
    Future Microbiol; 2010 Jul; 5(7):1109-23. PubMed ID: 20632809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of bacteriophage-derived endolysins to combat streptococcal disease: current state and perspectives.
    Linden SB; Alreja AB; Nelson DC
    Curr Opin Biotechnol; 2021 Apr; 68():213-220. PubMed ID: 33529969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing biofilms of clinically relevant organisms using bacteriophage.
    Donlan RM
    Trends Microbiol; 2009 Feb; 17(2):66-72. PubMed ID: 19162482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of an Endolysin Targeting
    Mondal SI; Akter A; Draper LA; Ross RP; Hill C
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073633
    [No Abstract]   [Full Text] [Related]  

  • 40. Delivering phage therapy per os: benefits and barriers.
    Zelasko S; Gorski A; Dabrowska K
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.